Payment overview · 2025
General Payments
$4,612.79
89 reported records · 29 companies
Healthcare provider profile · identity verified
Fadi Saba, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · ST PETERSBURG, FL · NPI 1588658348
Verified facts
What the public records show
CMS Open Payments records show Fadi Saba, M.D. received $4,612.79 in general payments during 2025 across 89 reported records.
Bayer Healthcare Pharmaceuticals Inc. accounted for 64.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 39 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Airsupra, Austedo Xr, Creon, Eliquis, Ingrezza, Jardiance, Linzess, Ozempic, Paxlovid, Rexulti, Rybelsus, Trelegy Ellipta, Vraylar, Xifaxan.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 89 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LUMIGAN as an associated drug or biological on 25016 records involving 7645 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Lumigan by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AIRSUPRA as an associated drug or biological on 165148 records involving 56069 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Airsupra by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 269 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Lokelma by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 133 claims for Symbicort by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 1858 claims for Eliquis by this doctor in 2024.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Biktarvy as an associated drug or biological on 8065 records involving 2759 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Biktarvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 206 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 211 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 195 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Rexulti by this doctor in 2024.
Neurocrine BioSciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INGREZZA as an associated drug or biological on 126456 records involving 27390 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Ingrezza by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Fiasp as an associated drug or biological on 15 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 83 claims for Fiasp by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 166 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Rybelsus by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Nuedexta by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 1858 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Paxlovid by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XIFAXAN as an associated drug or biological on 101901 records involving 33018 distinct recipient NPIs. Public Medicare Part D data also shows 145 claims for Xifaxan by this doctor in 2024.
Teva Pharmaceuticals USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AUSTEDO XR as an associated drug or biological on 86263 records involving 23643 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Austedo Xr by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $2,957.44 | 64.1% | 9 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $203.15 | 4.4% | 11 | 2025 |
| Cipher Pharmaceuticals US LLC | Unresolved — no canonical attribution shown | $195.43 | 4.2% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $186.15 | 4.0% | 10 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $141.80 | 3.1% | 12 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $115.17 | 2.5% | 7 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $73.65 | 1.6% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $70.30 | 1.5% | 4 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $67.69 | 1.5% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $62.16 | 1.4% | 3 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $60.42 | 1.3% | 3 | 2025 |
| Mannkind Corporation | Unresolved — no canonical attribution shown | $42.50 | 0.9% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $41.53 | 0.9% | 2 | 2025 |
| Insmed, Inc. | Unresolved — no canonical attribution shown | $41.06 | 0.9% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $38.81 | 0.8% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $38.20 | 0.8% | 2 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $36.30 | 0.8% | 2 | 2025 |
| Tonix Medicines, Inc. | Unresolved — no canonical attribution shown | $27.21 | 0.6% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $24.27 | 0.5% | 1 | 2025 |
| SCPHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $23.96 | 0.5% | 1 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $22.50 | 0.5% | 1 | 2025 |
| Seqirus USA Inc | Unresolved — no canonical attribution shown | $21.61 | 0.5% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $20.70 | 0.5% | 1 | 2025 |
| Hologic Sales and Service, LLC | Unresolved — no canonical attribution shown | $19.82 | 0.4% | 1 | 2025 |
| Smith+Nephew, Inc. | Unresolved — no canonical attribution shown | $19.31 | 0.4% | 1 | 2025 |
| Actelion Pharmaceuticals US, Inc. | Unresolved — no canonical attribution shown | $17.40 | 0.4% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $15.58 | 0.3% | 1 | 2025 |
| Renalytix AI, Inc. | Unresolved — no canonical attribution shown | $14.75 | 0.3% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $13.92 | 0.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Consulting Fee | $2,609.50 | 1 |
| Food and Beverage | $1,886.07 | 86 |
| Travel and Lodging | $74.72 | 1 |
| Education | $42.50 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $2,957.44 | 9 | 2025 |
Source payment records
|
|||||
| Natroba Normalized: natroba |
Drug | Cipher Pharmaceuticals US LLC | $195.43 | 1 | 2025 |
Source payment records
|
|||||
| Spinosad Normalized: spinosad |
Drug | Cipher Pharmaceuticals US LLC | $195.43 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $141.80 | 12 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $115.17 | 7 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $79.73 | 4 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $75.00 | 4 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $73.76 | 4 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 2 Normalized: freestyle libre 2 |
Device | Abbott Laboratories | $73.65 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $70.30 | 4 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $67.69 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $62.16 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $56.04 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $53.10 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $52.83 | 3 | 2025 |
Source payment records
|
|||||
| AFREZZA Normalized: afrezza |
Drug | Mannkind Corporation | $42.50 | 1 | 2025 |
Source payment records
|
|||||
| Arikayce Normalized: arikayce |
Drug | Insmed, Inc. | $41.06 | 2 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $39.75 | 3 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $39.75 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $38.81 | 2 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $36.30 | 2 | 2025 |
Source payment records
|
|||||
| BOTOX Normalized: botox |
Biological | ABBVIE INC. | $32.36 | 2 | 2025 |
Source payment records
|
|||||
| TONMYA Normalized: tonmya |
Drug | Tonix Medicines, Inc. | $27.21 | 1 | 2025 |
Source payment records
|
|||||
| KEVEYIS Normalized: keveyis |
Drug | Xeris Pharmaceuticals, Inc. | $24.27 | 1 | 2025 |
Source payment records
|
|||||
| FUROSCIX Normalized: furoscix |
Drug | SCPHARMACEUTICALS INC. | $23.96 | 1 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $22.50 | 1 | 2025 |
Source payment records
|
|||||
| Fluad Normalized: fluad |
Biological | Seqirus USA Inc | $21.61 | 1 | 2025 |
Source payment records
|
|||||
| Flucelvax Normalized: flucelvax |
Biological | Seqirus USA Inc | $21.61 | 1 | 2025 |
Source payment records
|
|||||
| COBENFY Normalized: cobenfy |
Drug | E.R. Squibb & Sons, L.L.C. | $20.70 | 1 | 2025 |
Source payment records
|
|||||
| APTIMA Normalized: aptima |
Device | Hologic Sales and Service, LLC | $19.82 | 1 | 2025 |
Source payment records
|
|||||
| THINPREP 2000 PROCESSOR Normalized: thinprep 2000 processor |
Device | Hologic Sales and Service, LLC | $19.82 | 1 | 2025 |
Source payment records
|
|||||
| COLLAGENASE SANTYL Normalized: collagenase santyl |
Drug | Smith+Nephew, Inc. | $19.31 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $19.18 | 1 | 2025 |
Source payment records
|
|||||
| Brinsupri Normalized: brinsupri |
Drug | Insmed, Inc. | $18.61 | 1 | 2025 |
Source payment records
|
|||||
| VYNDAQEL Normalized: vyndaqel |
Drug | PFIZER INC. | $17.79 | 1 | 2025 |
Source payment records
|
|||||
| UPTRAVI Normalized: uptravi |
Drug | Actelion Pharmaceuticals US, Inc. | $17.40 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $15.58 | 1 | 2025 |
Source payment records
|
|||||
| KIDNEYINTELX BLOOD COLLECTION CONVENIENCE KIT Normalized: kidneyintelx blood collection convenience kit |
Device | Renalytix AI, Inc. | $14.75 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $13.92 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AIRSUPRA airsupra |
2025 | Airsupra | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| AUSTEDO XR austedo xr |
2025 | Austedo Xr | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| CREON creon |
2025 | Creon | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 1858 | exact normalized | Medicare Part D |
| INGREZZA ingrezza |
2025 | Ingrezza | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 211 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 89 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 166 | exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 23 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 37 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 206 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 29 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| XIFAXAN xifaxan |
2025 | Xifaxan | 2024 | 145 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
89 | 30 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LUMIGAN open payments reported associated product |
CMS Open Payments — General Payments 25016 supporting records · 7645 recipient NPIs · example record 1201352548 |
Lumigan · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | AIRSUPRA open payments reported associated product |
CMS Open Payments — General Payments 165148 supporting records · 56069 recipient NPIs · example record 1206131344 |
Airsupra · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
49 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
269 | 47 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
133 | 43 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
1858 | 246 |
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Biktarvy open payments reported associated product |
CMS Open Payments — General Payments 8065 supporting records · 2759 recipient NPIs · example record 1234350766 |
Biktarvy · 2024 Exact normalized brand match · 1 Part D row |
51 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
206 | 51 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
211 | 39 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
70 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
195 | 37 |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Neurocrine BioSciences, Inc. Exact reporting entity; no affiliate inference |
2025 | INGREZZA open payments reported associated product |
CMS Open Payments — General Payments 126456 supporting records · 27390 recipient NPIs · example record 1242766729 |
Ingrezza · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Fiasp open payments reported associated product |
CMS Open Payments — General Payments 15 supporting records · 15 recipient NPIs · example record 1188262936 |
Fiasp · 2024 Exact normalized brand match · 1 Part D row |
83 | 24 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
166 | 42 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
37 | 11 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
16 | 16 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
1858 | 246 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
23 | 23 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | XIFAXAN open payments reported associated product |
CMS Open Payments — General Payments 101901 supporting records · 33018 recipient NPIs · example record 1231775337 |
Xifaxan · 2024 Exact normalized brand match · 1 Part D row |
145 | 13 |
| Teva Pharmaceuticals USA, Inc. Exact reporting entity; no affiliate inference |
2025 | AUSTEDO XR open payments reported associated product |
CMS Open Payments — General Payments 86263 supporting records · 23643 recipient NPIs · example record 1247244228 |
Austedo Xr · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 2778 | 657 |
| Eliquis | Apixaban | 1858 | 246 |
| Levothyroxine Sodium | Levothyroxine Sodium | 1648 | 300 |
| Gabapentin | Gabapentin | 1567 | 328 |
| Amlodipine Besylate | Amlodipine Besylate | 1565 | 375 |
| Lisinopril | Lisinopril | 1379 | 315 |
| Furosemide | Furosemide | 1191 | 252 |
| Metformin Hcl | Metformin Hcl | 1179 | 270 |
| Metoprolol Tartrate | Metoprolol Tartrate | 1119 | 251 |
| Trazodone Hcl | Trazodone Hcl | 967 | 219 |
| Tamsulosin Hcl | Tamsulosin Hcl | 961 | 207 |
| Losartan Potassium | Losartan Potassium | 939 | 250 |
| Levetiracetam | Levetiracetam | 821 | 126 |
| Potassium Chloride | Potassium Chloride | 798 | 168 |
| Famotidine | Famotidine | 782 | 175 |
| Pantoprazole Sodium | Pantoprazole Sodium | 716 | 174 |
| Omeprazole | Omeprazole | 703 | 198 |
| Clopidogrel | Clopidogrel Bisulfate | 698 | 149 |
| Divalproex Sodium | Divalproex Sodium | 619 | 118 |
| Carvedilol | Carvedilol | 615 | 143 |
| Simvastatin | Simvastatin | 598 | 151 |
| Mirtazapine | Mirtazapine | 537 | 150 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 529 | 145 |
| Sertraline Hcl | Sertraline Hcl | 475 | 108 |
| Buspirone Hcl | Buspirone Hcl | 474 | 105 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 458 | 184 |
| Montelukast Sodium | Montelukast Sodium | 457 | 94 |
| Metoprolol Succinate | Metoprolol Succinate | 450 | 122 |
| Duloxetine Hcl | Duloxetine Hcl | 415 | 101 |
| Donepezil Hcl | Donepezil Hcl | 405 | 96 |
| Escitalopram Oxalate | Escitalopram Oxalate | 401 | 93 |
| Baclofen | Baclofen | 399 | 82 |
| Alprazolam | Alprazolam | 398 | 105 |
| Tramadol Hcl | Tramadol Hcl | 393 | 97 |
| Fluticasone Propionate | Fluticasone Propionate | 387 | 158 |
| Quetiapine Fumarate | Quetiapine Fumarate | 358 | 86 |
| Meloxicam | Meloxicam | 355 | 99 |
| Xarelto | Rivaroxaban | 335 | 48 |
| Ondansetron Hcl | Ondansetron Hcl | 321 | 137 |
| Hydrochlorothiazide | Hydrochlorothiazide | 317 | 87 |
| Nifedipine Er | Nifedipine | 302 | 78 |
| Lactulose | Lactulose | 298 | 72 |
| Bumetanide | Bumetanide | 292 | 59 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 284 | 59 |
| Fluoxetine Hcl | Fluoxetine Hcl | 280 | 54 |
| Risperidone | Risperidone | 279 | 54 |
| Hydralazine Hcl | Hydralazine Hcl | 276 | 76 |
| Farxiga | Dapagliflozin Propanediol | 269 | 47 |
| Olanzapine | Olanzapine | 261 | 46 |
| Januvia | Sitagliptin Phosphate | 259 | 42 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 256 | 81 |
| Memantine Hcl | Memantine Hcl | 254 | 55 |
| Lamotrigine | Lamotrigine | 250 | 45 |
| Azithromycin | Azithromycin | 247 | 181 |
| Citalopram Hbr | Citalopram Hydrobromide | 244 | 53 |
| Spironolactone | Spironolactone | 228 | 58 |
| Clonazepam | Clonazepam | 226 | 47 |
| Lorazepam | Lorazepam | 219 | 54 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 212 | 40 |
| Benztropine Mesylate | Benztropine Mesylate | 211 | 30 |
| Finasteride | Finasteride | 211 | 48 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 211 | 46 |
| Jardiance | Empagliflozin | 211 | 39 |
| Tizanidine Hcl | Tizanidine Hcl | 210 | 38 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 206 | 51 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 203 | 62 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 202 | 153 |
| Glipizide | Glipizide | 202 | 40 |
| Pregabalin | Pregabalin | 201 | 39 |
| Midodrine Hcl | Midodrine Hcl | 196 | 52 |
| Trulicity | Dulaglutide | 195 | 37 |
| Allopurinol | Allopurinol | 191 | 44 |
| Ropinirole Hcl | Ropinirole Hcl | 188 | 38 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 182 | 30 |
| Latanoprost | Latanoprost | 181 | 46 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 177 | 50 |
| Gemtesa | Vibegron | 175 | 14 |
| Cephalexin | Cephalexin | 168 | 90 |
| Sucralfate | Sucralfate | 168 | 39 |
| Prednisone | Prednisone | 167 | 55 |
| Ozempic | Semaglutide | 166 | 42 |
| Amiodarone Hcl | Amiodarone Hcl | 161 | 38 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 153 | 37 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 152 | 45 |
| Zolpidem Tartrate | Zolpidem Tartrate | 148 | 39 |
| Pravastatin Sodium | Pravastatin Sodium | 146 | 34 |
| Xifaxan | Rifaximin | 145 | 13 |
| Mupirocin | Mupirocin | 142 | 72 |
| Oxybutynin Chloride | Oxybutynin Chloride | 141 | 31 |
| Lubiprostone | Lubiprostone | 140 | 36 |
| Atenolol | Atenolol | 137 | 27 |
| Methylprednisolone | Methylprednisolone | 137 | 111 |
| Breo Ellipta | Fluticasone/Vilanterol | 136 | 28 |
| Doxycycline Hyclate | Doxycycline Hyclate | 135 | 84 |
| Symbicort | Budesonide/Formoterol Fumarate | 133 | 43 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 132 | 48 |
| Paroxetine Hcl | Paroxetine Hcl | 132 | 44 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 131 | 58 |
| Ibuprofen | Ibuprofen | 129 | 59 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 129 | 48 |
| Clonidine Hcl | Clonidine Hcl | 127 | 40 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 126 | 33 |
| Topiramate | Topiramate | 126 | 28 |
| Metoclopramide Hcl | Metoclopramide Hcl | 123 | 22 |
| Temazepam | Temazepam | 123 | 24 |
| Entresto | Sacubitril/Valsartan | 121 | 18 |
| Dicyclomine Hcl | Dicyclomine Hcl | 120 | 27 |
| Aripiprazole | Aripiprazole | 119 | 29 |
| Ezetimibe | Ezetimibe | 118 | 28 |
| Ondansetron Odt | Ondansetron | 115 | 39 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 113 | 51 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 112 | 83 |
| Bupropion Xl | Bupropion Hcl | 109 | 30 |
| Ketoconazole | Ketoconazole | 109 | 43 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 108 | 61 |
| Testosterone Cypionate | Testosterone Cypionate | 107 | 22 |
| Digoxin | Digoxin | 106 | 18 |
| Fenofibrate | Fenofibrate Nanocrystallized | 104 | 20 |
| Oxycodone Hcl | Oxycodone Hcl | 104 | 38 |
| Lidocaine | Lidocaine | 102 | 29 |
| Nystatin | Nystatin | 102 | 67 |
| Diltiazem Hcl | Diltiazem Hcl | 101 | 23 |
| Propranolol Hcl | Propranolol Hcl | 100 | 24 |
| Celecoxib | Celecoxib | 99 | 29 |
| Warfarin Sodium | Warfarin Sodium | 99 | 12 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 97 | 22 |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 97 | 34 |
| Doxazosin Mesylate | Doxazosin Mesylate | 94 | 16 |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 94 | 19 |
| Glimepiride | Glimepiride | 93 | 26 |
| Alendronate Sodium | Alendronate Sodium | 92 | 24 |
| Meclizine Hcl | Meclizine Hcl | 92 | 25 |
| Linzess | Linaclotide | 89 | 30 |
| Breyna | Budesonide/Formoterol Fumarate | 87 | 29 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 87 | 21 |
| Ammonium Lactate | Ammonium Lactate | 86 | 49 |
| Bupropion Hcl Sr | Bupropion Hcl | 86 | 21 |
| Fluconazole | Fluconazole | 86 | 52 |
| Diclofenac Sodium | Diclofenac Sodium | 85 | 36 |
| Metformin Hcl Er | Metformin Hcl | 84 | 29 |
| Myrbetriq | Mirabegron | 84 | 18 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 84 | 71 |
| Fenofibrate | Fenofibrate | 83 | 19 |
| Fiasp | Insulin Aspart (Niacinamide) | 83 | 24 |
| Vascepa | Icosapent Ethyl | 83 | suppressed |
| Levemir | Insulin Detemir | 81 | 31 |
| Nitroglycerin | Nitroglycerin | 81 | 46 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 79 | 28 |
| Ertapenem | Ertapenem Sodium | 77 | 38 |
| Levofloxacin | Levofloxacin | 76 | 49 |
| Primidone | Primidone | 76 | 15 |
| Brimonidine Tartrate | Brimonidine Tartrate | 75 | 14 |
| Methocarbamol | Methocarbamol | 74 | 28 |
| Methimazole | Methimazole | 73 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 73 | 17 |
| Santyl | Collagenase Clostridium Hist. | 73 | 51 |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 71 | 24 |
| Fenofibrate | Fenofibrate,micronized | 70 | 11 |
| Mounjaro | Tirzepatide | 70 | 14 |
| Novolog | Insulin Aspart | 70 | 32 |
| Permethrin | Permethrin | 70 | 45 |
| Nyamyc | Nystatin | 69 | 35 |
| Terazosin Hcl | Terazosin Hcl | 69 | 14 |
| Ceftriaxone | Ceftriaxone Sodium | 68 | 35 |
| Diazepam | Diazepam | 68 | 20 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 68 | 17 |
| Amantadine | Amantadine Hcl | 66 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 65 | 13 |
| Pioglitazone Hcl | Pioglitazone Hcl | 65 | 17 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 64 | 16 |
| Tresiba Flextouch U-100 | Insulin Degludec | 64 | 13 |
| Carbamazepine | Carbamazepine | 62 | 13 |
| Megestrol Acetate | Megestrol Acetate | 62 | 19 |
| Namzaric | Memantine Hcl/Donepezil Hcl | 62 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 61 | 34 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 60 | 14 |
| Enalapril Maleate | Enalapril Maleate | 60 | 11 |
| Incruse Ellipta | Umeclidinium Bromide | 59 | 13 |
| Methenamine Hippurate | Methenamine Hippurate | 58 | 16 |
| Timolol Maleate | Timolol Maleate | 58 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 57 | 15 |
| Prednisolone Acetate | Prednisolone Acetate | 57 | 16 |
| Ramipril | Ramipril | 57 | 11 |
| Novolog Flexpen | Insulin Aspart | 56 | 18 |
| Sevelamer Carbonate | Sevelamer Carbonate | 56 | suppressed |
| Folic Acid | Folic Acid | 55 | 16 |
| Insulin Aspart | Insulin Aspart | 53 | 29 |
| Labetalol Hcl | Labetalol Hcl | 53 | 16 |
| Ranolazine Er | Ranolazine | 53 | 16 |
| Pentoxifylline | Pentoxifylline | 52 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 52 | 18 |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 51 | suppressed |
| Amoxicillin | Amoxicillin | 50 | 35 |
| Lovastatin | Lovastatin | 50 | 11 |
| Brilinta | Ticagrelor | 49 | suppressed |
| Vancomycin Hcl | Vancomycin Hcl | 49 | 14 |
| Brimonidine Tartrate-Timolol | Brimonidine Tartrate/Timolol | 48 | suppressed |
| Hydrocortisone | Hydrocortisone | 48 | 28 |
| Humalog Kwikpen U-100 | Insulin Lispro | 47 | 21 |
| Clozapine | Clozapine | 46 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 46 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 45 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 44 | suppressed |
| Haloperidol | Haloperidol | 44 | suppressed |
| Insulin Lispro | Insulin Lispro | 44 | 15 |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 43 | 30 |
| Loperamide | Loperamide Hcl | 43 | 23 |
| Morphine Sulfate Er | Morphine Sulfate | 43 | suppressed |
| Valsartan | Valsartan | 43 | 13 |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 42 | 13 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 41 | 17 |
| Nystop | Nystatin | 41 | 24 |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 40 | 12 |
| Albuterol Sulfate | Albuterol Sulfate | 39 | 17 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 39 | 20 |
| Colchicine | Colchicine | 39 | 11 |
| Levemir Flexpen | Insulin Detemir | 39 | 21 |
| Metolazone | Metolazone | 39 | 12 |
| Metronidazole | Metronidazole | 39 | 26 |
| Tiagabine Hcl | Tiagabine Hcl | 39 | suppressed |
| Cefdinir | Cefdinir | 38 | 35 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 38 | 13 |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 38 | 18 |
| Sodium Chloride | 0.9 % Sodium Chloride | 38 | 23 |
| Azelastine Hcl | Azelastine Hcl | 37 | 11 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 37 | 15 |
| Lidocaine Hcl | Lidocaine Hcl/Pf | 37 | 28 |
| Rybelsus | Semaglutide | 37 | 11 |
| Isosorbide Mononitrate | Isosorbide Mononitrate | 36 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 35 | 12 |
| Emtricitabine-Tenofovir Disop | Emtricitabine/Tenofovir (Tdf) | 35 | suppressed |
| Torsemide | Torsemide | 35 | 11 |
| Ethambutol Hcl | Ethambutol Hcl | 34 | suppressed |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 33 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 33 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 33 | suppressed |
| Rhopressa | Netarsudil Mesylate | 33 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl | 32 | 24 |
| Meropenem | Meropenem | 32 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 32 | 13 |
| Anastrozole | Anastrozole | 31 | suppressed |
| Chlorthalidone | Chlorthalidone | 31 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 31 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 31 | suppressed |
| Ssd | Silver Sulfadiazine | 31 | 13 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 30 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 30 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 30 | suppressed |
| Naproxen | Naproxen | 30 | suppressed |
| Tradjenta | Linagliptin | 30 | suppressed |
| Calcitriol | Calcitriol | 29 | 14 |
| Gemfibrozil | Gemfibrozil | 29 | suppressed |
| Glipizide Er | Glipizide | 29 | suppressed |
| Movantik | Naloxegol Oxalate | 29 | suppressed |
| Ofloxacin | Ofloxacin | 29 | suppressed |
| Vraylar | Cariprazine Hcl | 29 | suppressed |
| Acyclovir | Acyclovir | 28 | 11 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 28 | 11 |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 28 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 28 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 27 | suppressed |
| Humalog | Insulin Lispro | 27 | 11 |
| Tivicay | Dolutegravir Sodium | 27 | suppressed |
| Trihexyphenidyl Hcl | Trihexyphenidyl Hcl | 27 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 26 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 26 | 11 |
| Acarbose | Acarbose | 25 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 25 | 13 |
| Clonidine | Clonidine | 25 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 25 | 14 |
| Invokana | Canagliflozin | 25 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 25 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 25 | suppressed |
| Dalfampridine Er | Dalfampridine | 24 | suppressed |
| Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 24 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 24 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 23 | suppressed |
| Creon | Lipase/Protease/Amylase | 23 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 23 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 23 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 23 | 23 |
| Solifenacin Succinate | Solifenacin Succinate | 23 | 11 |
| Synthroid | Levothyroxine Sodium | 23 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 22 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 22 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 22 | suppressed |
| Kapspargo Sprinkle | Metoprolol Succinate | 22 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 22 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 21 | 19 |
| Daptomycin | Daptomycin | 21 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 21 | suppressed |
| Ingrezza | Valbenazine Tosylate | 21 | suppressed |
| Nadolol | Nadolol | 21 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 21 | suppressed |
| Valproic Acid | Valproic Acid | 21 | suppressed |
| Atovaquone | Atovaquone | 20 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 20 | suppressed |
| Ciclopirox | Ciclopirox | 20 | 13 |
| Dapagliflozin | Dapagliflozin Propanediol | 20 | 13 |
| Meloxicam | Meloxicam, Submicronized | 20 | suppressed |
| Premarin | Estrogens, Conjugated | 20 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 20 | suppressed |
| Verapamil Er | Verapamil Hcl | 20 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 19 | suppressed |
| Clotrimazole | Clotrimazole | 19 | 15 |
| Donepezil Hcl Odt | Donepezil Hcl | 19 | suppressed |
| Dulera | Mometasone/Formoterol | 19 | suppressed |
| Humulin R | Insulin Regular, Human | 19 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 19 | suppressed |
| Novolin R Flexpen | Insulin Regular, Human | 19 | suppressed |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 19 | 13 |
| Risperdal Consta | Risperidone Microspheres | 19 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 19 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 19 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 18 | suppressed |
| Fluphenazine Decanoate | Fluphenazine Decanoate | 18 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 18 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 17 | suppressed |
| Chlorzoxazone | Chlorzoxazone | 17 | suppressed |
| Combigan | Brimonidine Tartrate/Timolol | 17 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 17 | suppressed |
| Glucagon Emergency Kit | Glucagon | 17 | 12 |
| Jantoven | Warfarin Sodium | 17 | suppressed |
| Lumigan | Bimatoprost | 17 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 17 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 17 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 17 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 17 | suppressed |
| Restasis | Cyclosporine | 17 | suppressed |
| Ritonavir | Ritonavir | 17 | suppressed |
| Zonisamide | Zonisamide | 17 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 16 | 16 |
| Airsupra | Albuterol Sulfate/Budesonide | 16 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 16 | suppressed |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 16 | suppressed |
| Carbamazepine Er | Carbamazepine | 16 | suppressed |
| Dexamethasone | Dexamethasone | 16 | 13 |
| Flecainide Acetate | Flecainide Acetate | 16 | suppressed |
| Formoterol Fumarate | Formoterol Fumarate | 16 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 16 | suppressed |
| Rexulti | Brexpiprazole | 16 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 16 | suppressed |
| Teriflunomide | Teriflunomide | 16 | suppressed |
| Ursodiol | Ursodiol | 16 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Budesonide | Budesonide | 15 | suppressed |
| Cefepime Hcl | Cefepime Hcl | 15 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 15 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 15 | 13 |
| Humulin N Kwikpen | Insulin Nph Human Isophane | 15 | suppressed |
| Nuplazid | Pimavanserin Tartrate | 15 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 15 | suppressed |
| Scopolamine | Scopolamine | 15 | suppressed |
| Tiotropium Bromide | Tiotropium Bromide | 15 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 15 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 14 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 14 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 14 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 14 | suppressed |
| Eplerenone | Eplerenone | 14 | suppressed |
| Ethosuximide | Ethosuximide | 14 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 14 | suppressed |
| Lacosamide | Lacosamide | 14 | suppressed |
| Lyumjev Kwikpen U-100 | Insulin Lispro-Aabc | 14 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 14 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 14 | suppressed |
| Acitretin | Acitretin | 13 | suppressed |
| Austedo Xr | Deutetrabenazine | 13 | suppressed |
| Chlorpromazine Hcl | Chlorpromazine Hcl | 13 | suppressed |
| Dutasteride | Dutasteride | 13 | suppressed |
| Estradiol | Estradiol | 13 | suppressed |
| Fluticasone-Vilanterol | Fluticasone/Vilanterol | 13 | suppressed |
| Fosamprenavir Calcium | Fosamprenavir Calcium | 13 | suppressed |
| Ivermectin | Ivermectin | 13 | 12 |
| Linezolid | Linezolid | 13 | suppressed |
| Mesalamine Er | Mesalamine | 13 | suppressed |
| Modafinil | Modafinil | 13 | suppressed |
| Steglatro | Ertugliflozin Pidolate | 13 | suppressed |
| Atrovent Hfa | Ipratropium Bromide | 12 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 12 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 12 | suppressed |
| Fluphenazine Hcl | Fluphenazine Hcl | 12 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 12 | suppressed |
| Methenamine Mandelate | Methenamine Mandelate | 12 | suppressed |
| Simbrinza | Brinzolamide/Brimonidine Tart | 12 | suppressed |
| Testosterone | Testosterone | 12 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| True Comfort Pro Alcohol Pads | Alcohol Antiseptic Pads | 12 | suppressed |
| Admelog Solostar | Insulin Lispro | 11 | suppressed |
| Calcium Acetate | Calcium Acetate | 11 | suppressed |
| Cholestyramine Light | Cholestyramine | 11 | suppressed |
| Copaxone | Glatiramer Acetate | 11 | suppressed |
| Enulose | Lactulose | 11 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 11 | suppressed |
| Invokamet Xr | Canagliflozin/Metformin Hcl | 11 | suppressed |
| Mesalamine | Mesalamine | 11 | suppressed |
| Phenobarbital | Phenobarbital | 11 | suppressed |
| Sps | Sodium Polystyrene Sulfon/Sorb | 11 | suppressed |
| Telmisartan | Telmisartan | 11 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $4,612.79 · 89 records | Bayer Healthcare Pharmaceuticals Inc. | AFREZZA, AIRSUPRA, APTIMA, AUSTEDO XR, Arikayce, BOTOX, Brinsupri, CAPLYTA, COBENFY, COLLAGENASE SANTYL, CREON, Dexcom G6 Transmitter, ELIQUIS, FREESTYLE LIBRE 2, FUROSCIX, Fluad, Flucelvax, IBSRELA, INGREZZA, JARDIANCE, KEVEYIS, KIDNEYINTELX BLOOD COLLECTION CONVENIENCE KIT, Kerendia, LINZESS, Natroba, Ozempic, PAXLOVID, QULIPTA, REXULTI, Rybelsus, Spinosad, THINPREP 2000 PROCESSOR, TONMYA, TRELEGY ELLIPTA, UBRELVY, UPTRAVI, VRAYLAR, VYNDAQEL, XIFAXAN | 29 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Airsupra play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error